Video
How new avelumab data add to knowledge of treatment’s use as maintenance therapy
Author(s):
“I think the data from this particular abstract pretty much reinforce that if you get avelumab as maintenance therapy, the time that patients spend in first- and second-line therapy is prolonged compared to patients who get best supportive care,” says Petros Grivas, MD, PhD.
In this video, Petros Grivas, MD, PhD, discusses the significance of the findings from the abstract, “Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100,” which was presented at the 2021 American Society of Clinical Oncology annual meeting.
Grivas is global co-principal investigator on the JAVELIN Bladder 100 trial and associate professor and clinical director of the Genitourinary Cancers Program at Seattle Cancer Care Alliance, and associate professor, Division of Medical Oncology, University of Washington School of Medicine.
